What Is Herd Immunity and How Does It Actually Work

What exactly is herd immunity?

Herd immunity is a form of indirect population-level protection that emerges when a large enough fraction of people has become immune to a disease. When an infected person moves through the community, they mostly encounter immune individuals who cannot catch or spread the pathogen. The chain of transmission keeps breaking before it can reach someone who is susceptible. As a result, even people who are not themselves immune receive protection because potential transmitters around them have been effectively removed from the equation.

How is the herd immunity threshold calculated?

The threshold depends on how contagious a disease is, described by its basic reproduction number, written as R0 and pronounced "R-naught." R0 represents the average number of additional people one infected person would infect in a completely susceptible population with no interventions. The formula for the herd immunity threshold (HIT) is straightforward:

HIT = 1 − (1 / R0)

If R0 is 2, the HIT is 50 percent: once half the population is immune, each infected person on average infects fewer than one other person, and the outbreak shrinks rather than grows. If R0 is 10, the HIT rises to 90 percent. The relationship is not linear: highly contagious diseases demand disproportionately high coverage, which is why even small drops in vaccination rates can reignite outbreaks of the most transmissible diseases while having little visible effect on less contagious ones.

What thresholds apply to different diseases?

Measles is among the most contagious pathogens ever measured, with an R0 estimated at 12 to 18 in fully susceptible unvaccinated populations. Plugging those numbers into the formula gives a herd immunity threshold of 92 to 95 percent. This is why measles can resurge quickly when vaccination coverage dips by just a few percentage points in a community: the margin between protection and outbreak is extremely thin. The MMR vaccine provides coverage above 97 percent after two doses, which is why countries with high sustained vaccination historically eliminated endemic measles transmission entirely.

Seasonal influenza has an R0 around 1.2 to 1.4, yielding a threshold of roughly 17 to 29 percent. This lower bar partly explains why partial annual vaccination campaigns still meaningfully reduce flu burden even without achieving herd immunity: fewer transmitters still fewer cases, even if the chain never fully breaks. The original strain of SARS-CoV-2 carried an R0 around 2.5, suggesting a threshold near 60 percent, but the Delta and Omicron variants with R0 values estimated at 5 to 8 and above pushed the theoretical threshold to 80 percent or higher, which is why vaccine-induced herd immunity against transmission proved difficult to sustain against those variants.

Does it matter whether immunity comes from infection or vaccination?

Both routes produce immune memory cells that recognize a pathogen on subsequent exposure. The critical difference is cost. Natural infection provides immunity, but only to those who survive the disease without serious lasting harm. For a disease like measles, the natural route to population immunity would require a large wave of cases, with a predictable fraction resulting in encephalitis, deafness, and death before the threshold is crossed. Vaccines are specifically engineered to trigger the same immune recognition using inactivated virus, weakened strains, or specific proteins such as the spike protein in mRNA vaccines, without causing the disease itself.

Vaccination also allows immunity to be built across a population simultaneously and equitably rather than sequentially through outbreaks that inevitably hit the most vulnerable first. It is also worth acknowledging two real limitations of both routes: immunity from many vaccines and from natural infection wanes over time, requiring booster doses or periodic re-exposure; and pathogens that mutate rapidly, like influenza and some coronaviruses, can partially escape existing immune memory by changing their surface proteins, effectively raising the operative R0 and resetting the threshold calculation.

Who benefits most from herd immunity?

The people who benefit most from community immunity are those who cannot develop adequate protection themselves. Newborns have not yet completed their vaccine schedules and retain only partial immunity borrowed from their mothers. People undergoing chemotherapy for cancer have suppressed immune systems that may not respond normally to vaccines. Organ transplant recipients take immunosuppressant drugs to prevent rejection, which also blunts vaccine responses. Individuals with certain rare genetic immune deficiencies cannot produce antibodies at all. For all of these groups, their neighbors' immunity is their primary shield. When overall vaccination coverage falls below the herd immunity threshold, even temporarily or locally, these individuals face sharply elevated risk, which is why epidemiologists treat population-level coverage as a community obligation.